CN101595099B - 晶体盐酸度洛西汀 - Google Patents
晶体盐酸度洛西汀 Download PDFInfo
- Publication number
- CN101595099B CN101595099B CN2007800231697A CN200780023169A CN101595099B CN 101595099 B CN101595099 B CN 101595099B CN 2007800231697 A CN2007800231697 A CN 2007800231697A CN 200780023169 A CN200780023169 A CN 200780023169A CN 101595099 B CN101595099 B CN 101595099B
- Authority
- CN
- China
- Prior art keywords
- duloxetine hydrochloride
- solution
- crystalline duloxetine
- preparing crystalline
- duloxetine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0612508.2 | 2006-06-23 | ||
GBGB0612508.2A GB0612508D0 (en) | 2006-06-23 | 2006-06-23 | Crystalline duloxetine hydrochloride |
PCT/GB2007/002317 WO2007148096A1 (en) | 2006-06-23 | 2007-06-21 | Crystalline duloxetine hydrochloride |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101595099A CN101595099A (zh) | 2009-12-02 |
CN101595099B true CN101595099B (zh) | 2013-03-06 |
Family
ID=36803803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800231697A Expired - Fee Related CN101595099B (zh) | 2006-06-23 | 2007-06-21 | 晶体盐酸度洛西汀 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7795454B2 (ja) |
EP (1) | EP2035403A1 (ja) |
JP (1) | JP5247687B2 (ja) |
CN (1) | CN101595099B (ja) |
AU (1) | AU2007262794B2 (ja) |
BR (1) | BRPI0712454A2 (ja) |
CA (1) | CA2655962A1 (ja) |
GB (1) | GB0612508D0 (ja) |
NZ (1) | NZ572918A (ja) |
WO (1) | WO2007148096A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0612508D0 (en) | 2006-06-23 | 2006-08-02 | Arrow Int Ltd | Crystalline duloxetine hydrochloride |
US8278463B2 (en) | 2008-04-04 | 2012-10-02 | Ranbaxy Laboratories Limited | Process for the preparation of pure duloxetine hydrochloride |
CZ304602B6 (cs) * | 2009-09-02 | 2014-07-30 | Zentiva, K. S. | Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu) |
CN103626735A (zh) * | 2012-08-28 | 2014-03-12 | 石药集团中奇制药技术(石家庄)有限公司 | 一种盐酸度洛西汀晶型及其制备方法 |
JP6178817B2 (ja) * | 2015-04-27 | 2017-08-09 | 株式会社豊田中央研究所 | 光輝性塗料組成物、光輝性樹脂膜、及び、積層塗膜 |
CN106265528A (zh) * | 2015-05-12 | 2017-01-04 | 法德生技药品股份有限公司 | 制备药物凝集体的方法 |
JP7491934B2 (ja) | 2019-01-03 | 2024-05-28 | ディーエヌエー スクリプト | オリゴヌクレオチドセットのワンポット合成 |
CN113603673A (zh) * | 2020-11-16 | 2021-11-05 | 上海中西三维药业有限公司 | 一种盐酸度洛西汀的晶型、其制备方法及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005108386A1 (en) * | 2004-05-11 | 2005-11-17 | Cipla Limited | Crystalline forms of duloxetine free base |
WO2006071868A2 (en) * | 2004-12-23 | 2006-07-06 | Teva Pharmaceutical Industries Ltd. | Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof |
WO2006081515A2 (en) * | 2005-01-27 | 2006-08-03 | Teva Pharmaceutical Industries Ltd. | Duloxetine hydrochloride polymorphs |
EP1820800A1 (en) * | 2006-02-17 | 2007-08-22 | KRKA, tovarna zdravil, d.d., Novo mesto | Crystalline forms of duloxetine hydrochloride and processes for their preparation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
US5362886A (en) | 1993-10-12 | 1994-11-08 | Eli Lilly And Company | Asymmetric synthesis |
US20050197503A1 (en) | 2004-03-05 | 2005-09-08 | Boehringer Ingelheim International Gmbh | Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines |
US7550605B2 (en) | 2004-08-05 | 2009-06-23 | Sun Pharmaceutical Industries Ltd. | Process for preparation of an anitdepressant compound |
CZ297560B6 (cs) | 2004-10-26 | 2007-02-07 | Zentiva, A. S. | Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu) |
US20060211751A1 (en) | 2004-11-19 | 2006-09-21 | Reuven Izsak | Zolmitriptan crystal forms |
US20060116420A1 (en) | 2004-11-23 | 2006-06-01 | Ramakrishnan Chidambaram | Crystalline forms of 3'-tert-Butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel |
US7534900B2 (en) | 2005-03-14 | 2009-05-19 | Teva Pharmaceutical Industries Ltd | Process for the purification of duloxetine hydrochloride |
GB0612508D0 (en) | 2006-06-23 | 2006-08-02 | Arrow Int Ltd | Crystalline duloxetine hydrochloride |
-
2006
- 2006-06-23 GB GBGB0612508.2A patent/GB0612508D0/en not_active Ceased
-
2007
- 2007-06-21 JP JP2009515959A patent/JP5247687B2/ja not_active Expired - Fee Related
- 2007-06-21 CN CN2007800231697A patent/CN101595099B/zh not_active Expired - Fee Related
- 2007-06-21 CA CA002655962A patent/CA2655962A1/en not_active Abandoned
- 2007-06-21 AU AU2007262794A patent/AU2007262794B2/en not_active Ceased
- 2007-06-21 EP EP07733313A patent/EP2035403A1/en not_active Withdrawn
- 2007-06-21 BR BRPI0712454-6A patent/BRPI0712454A2/pt not_active IP Right Cessation
- 2007-06-21 WO PCT/GB2007/002317 patent/WO2007148096A1/en active Application Filing
- 2007-06-21 NZ NZ572918A patent/NZ572918A/en not_active IP Right Cessation
- 2007-06-22 US US11/821,290 patent/US7795454B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005108386A1 (en) * | 2004-05-11 | 2005-11-17 | Cipla Limited | Crystalline forms of duloxetine free base |
WO2006071868A2 (en) * | 2004-12-23 | 2006-07-06 | Teva Pharmaceutical Industries Ltd. | Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof |
WO2006081515A2 (en) * | 2005-01-27 | 2006-08-03 | Teva Pharmaceutical Industries Ltd. | Duloxetine hydrochloride polymorphs |
EP1820800A1 (en) * | 2006-02-17 | 2007-08-22 | KRKA, tovarna zdravil, d.d., Novo mesto | Crystalline forms of duloxetine hydrochloride and processes for their preparation |
Also Published As
Publication number | Publication date |
---|---|
CN101595099A (zh) | 2009-12-02 |
WO2007148096A1 (en) | 2007-12-27 |
JP2009541290A (ja) | 2009-11-26 |
AU2007262794B2 (en) | 2012-04-12 |
AU2007262794A1 (en) | 2007-12-27 |
CA2655962A1 (en) | 2007-12-27 |
JP5247687B2 (ja) | 2013-07-24 |
GB0612508D0 (en) | 2006-08-02 |
EP2035403A1 (en) | 2009-03-18 |
BRPI0712454A2 (pt) | 2012-10-02 |
US20080021090A1 (en) | 2008-01-24 |
US7795454B2 (en) | 2010-09-14 |
NZ572918A (en) | 2011-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101595099B (zh) | 晶体盐酸度洛西汀 | |
CA2558877A1 (en) | Solifenacin succinate-containing composition | |
CN105399694A (zh) | 药物Lesinurad轴手性对映体 | |
CN101627026A (zh) | 晶体盐酸度洛西汀 | |
CN101631783A (zh) | 晶体盐酸度洛西汀 | |
CN105622531A (zh) | 轴手性异构体及其制备方法和制药用途 | |
CN105524033A (zh) | 达格列净的富马酸共晶体、其制备方法及药物组合物 | |
EA017631B1 (ru) | Кристаллическое основание транс-1-((1r,3s)-3-фенил-6-хлороиндан-1-ил)-3,3-диметилпиперазина | |
JP2009541291A5 (ja) | ||
JP2009541292A5 (ja) | ||
TW202024035A (zh) | 用於製備(-)-琥珀酸西苯唑啉的新穎方法 | |
CN105431409A (zh) | 制备阿福特罗或其盐的方法 | |
CH637132A5 (de) | Verfahren zur herstellung neuer piperidylidenderivate von benzoxanthenen, -thioxanthenen und -dibenzoxepinen. | |
JP7282780B2 (ja) | 4-(ナフタレン-1-イル)-4h-1,2,4-トリアゾール系化合物の結晶形、塩形態及びその製造方法 | |
CN117362279A (zh) | Par-1抑制剂、其手性合成方法、及其盐晶型的制备方法与用途 | |
CN108640927A (zh) | 一种米尔贝肟的制备方法 | |
CN105399727A (zh) | 盐酸瑞伐拉赞新结晶形态 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130306 Termination date: 20140621 |
|
EXPY | Termination of patent right or utility model |